Real-World study reveals siponimod use in russian MS patients
NCT ID NCT07168694
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked back at medical records of 606 people with secondary progressive multiple sclerosis (SPMS) in Russia who were taking siponimod. Researchers wanted to understand patient characteristics and how the drug was used in everyday practice. The study collected data from 11 MS centers between April and September 2024.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- siponimod
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Could a common supplement fight fatigue in progressive MS?
- Nurse-Led video calls aim to empower MS patients
- Cheaper MS drug could match pricey standard in major trial
- Experimental cell therapy takes on multiple sclerosis